Acute myopathy in a patient with concomitant use of pravastatin and colchicine

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1358-1361

  Alayli, Gamze ^a   Cengiz, Kivanç ^a   Cantürk, Ferhan ^a   Durmuş, Dilek ^a   Akyol, Yeşim ^a   Menekşe, Elif B ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Colchicine; Pravastatin: Myopathy

Indexed keywords

ACETYLSALICYLIC ACID; COLCHICINE; CREATININE; CYTOCHROME P450; FUROSEMIDE; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PRAVASTATIN; SPIRONOLACTONE; UREA;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG METABOLISM; DRUG USE; DRUG WITHDRAWAL; ELECTROMYOGRAM; FEMALE; GOUT; HUMAN; KIDNEY DYSFUNCTION; MUSCLE WEAKNESS; MYOPATHY; NEUROTOXICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROBABILITY; UREA NITROGEN BLOOD LEVEL;

ACUTE DISEASE; AGED; COLCHICINE; DRUG INTERACTIONS; FEMALE; GOUT SUPPRESSANTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MUSCULAR DISEASES; PRAVASTATIN;

EID: 21744447883     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E593     Document Type: Article

References (20)

1. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998;28:48-59.
2. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep 2002;4:252-6.
3. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
4. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis Suppl 2002;3:35-40.
5. Tateishi T, Soucek P, Caraco Y, Guenrerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997;53:111-6.
6. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002;25:266-8.
7. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
8. Le Quintrec JS, Le Quintrec JL. Drug induced myopathies. Baillieres Clin Rheumatol 1991;5:21-38.
9. Naranjo CA, Busto U, Sellers EM, Sandor P Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10. Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy 1991;11:196-211.
11. Guis S, Mattei JP, Liote F. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol 2003;17:877-907.
12. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash) 2000;40:637-44.
13. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27:173-9.
14. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16.
15. Takikawa H, Sano N, Akimoto K, Ogasawara T, Yamanaka M. Effects of colchicine and phenothiazine on biliary excretion of organic anions in rats. J Gastroenterol Hepatol 1998;13:427-32.
16. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997;62:311-21.
17. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25: 2732-34.
18. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-14.
19. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004;24:1784-92.
20. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-9.